New treatment options have changed the survival of patients with follicular lymphoma.

Publication Type:

Journal Article

Authors:

Fisher, Richard I; LeBlanc, Michael; Press, Oliver W; Maloney, David G; Unger, Joseph M; Miller, Thomas P

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 23, Issue 33, p.8447-52 (2005)

Keywords:

Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Disease-Free Survival, Doxorubicin, Etoposide, Female, Humans, Leucovorin, Lymphoma, Follicular, Male, Mechlorethamine, methotrexate, Middle Aged, Multivariate Analysis, Prednisone, Procarbazine, Proportional Hazards Models, Prospective Studies, Survival Rate, United States, Vincristine

Abstract:

The natural history of follicular lymphoma is believed not to have changed over the last 30 years. Median survivals have ranged from 7 to 10 years, and the disease is considered incurable. However, multiple new treatment options have been developed in the last decade, and their impact on survival of follicular lymphoma remains unknown.